These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia. Murphy M; Close J; Lottenberg R; Rajasekhar A Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361 [No Abstract] [Full Text] [Related]
28. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055 [No Abstract] [Full Text] [Related]
29. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N Leuk Res; 2009 Dec; 33(12):e218-20. PubMed ID: 19525008 [No Abstract] [Full Text] [Related]
33. [Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib]. Sawadogo S; Hien FM; Ouédraogo MS; Drabo YJ Pan Afr Med J; 2014; 18():142. PubMed ID: 25419280 [TBL] [Abstract][Full Text] [Related]
34. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance? White DL Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091 [No Abstract] [Full Text] [Related]
35. New directions in the treatment of patients with chronic myeloid leukemia: introduction. Baccarani M Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542 [No Abstract] [Full Text] [Related]
36. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib. Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870 [No Abstract] [Full Text] [Related]
37. [Pregnancy and myeloid leukemia treated with imatinib. Development and monitoring of a patient]. Báez-de la Fuente E; Arellano-Severiano B Rev Med Inst Mex Seguro Soc; 2014; 52(3):342-5. PubMed ID: 24878098 [TBL] [Abstract][Full Text] [Related]
38. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790 [TBL] [Abstract][Full Text] [Related]
39. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Mukhopadhyay A; Dasgupta S; Kanti Ray U; Gharami F; Bose CK; Mukhopadhyay S Ir J Med Sci; 2015 Mar; 184(1):183-8. PubMed ID: 24590821 [TBL] [Abstract][Full Text] [Related]
40. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia. Ueda K; Horiike S; Zen K; Misawa S; Taniwaki M Leuk Lymphoma; 2006 Sep; 47(9):1967-9. PubMed ID: 17065015 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]